Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies

Wright, 2000, Meta-analysis of regional brain volumes in schizophrenia, Am J Psychiatry, 157, 16, 10.1176/ajp.157.1.16

Van Haren, 2008, Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood, Biol Psychiatry, 63, 106, 10.1016/j.biopsych.2007.01.004

Cahn, 2002, Brain volume changes in first-episode schizophrenia: a 1-year follow-up study, Arch Gen Psychiatry, 59, 1002, 10.1001/archpsyc.59.11.1002

Borgwardt, 2008, Reductions in frontal, temporal and parietal volume associated with the onset of psychosis, Schizophr Res, 106, 108, 10.1016/j.schres.2008.08.007

DeLisi, 2008, The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia, Schizophr Bull, 34, 312, 10.1093/schbul/sbm164

Pantelis, 2003, Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences, Aust N Z J Psychiatry, 37, 399, 10.1046/j.1440-1614.2003.01193.x

Hulshoff Pol, 2008, What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia, Schizophr Bull, 34, 354, 10.1093/schbul/sbm168

Harrison, 1999, The neuropathology of schizophrenia: a critical review of the data and their interpretation, Brain, 122, 593, 10.1093/brain/122.4.593

Brans, 2008, Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia, Arch Gen Psychiatry, 65, 1259, 10.1001/archpsyc.65.11.1259

Harrison, 2005, Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence, Mol Psychiatry, 10, 40, 10.1038/sj.mp.4001558

Cull-Candy, 2001, NMDA receptor subunits: diversity, development and disease, Curr Opin Neurobiol, 11, 327, 10.1016/S0959-4388(00)00215-4

Paoletti, 2007, NMDA receptor subunits: function and pharmacology, Curr Opin Pharmacol, 7, 39, 10.1016/j.coph.2006.08.011

Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch Gen Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004

Olney, 1995, Glutamate receptor dysfunction and schizophrenia, Arch Gen Psychiatry, 52, 998, 10.1001/archpsyc.1995.03950240016004

Moghaddam, 1997, Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex, J Neurosci, 17, 2921, 10.1523/JNEUROSCI.17-08-02921.1997

Adams, 1998, Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine, J Neurosci, 18, 5545, 10.1523/JNEUROSCI.18-14-05545.1998

Olney, 1999, NMDA receptor hypofunction model of schizophrenia, J Psychiatr Res, 33, 523, 10.1016/S0022-3956(99)00029-1

Kondziella, 2007, How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?, Neurochem Int, 50, 291, 10.1016/j.neuint.2006.09.006

Stone, 2007, Review: Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review, J Psychopharmacol, 21, 440, 10.1177/0269881106073126

Kaiser, 2005, Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T, Neurobiol Aging, 26, 665, 10.1016/j.neurobiolaging.2004.07.001

Rothman, 2003, In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function, Annu Rev Physiol, 65, 401, 10.1146/annurev.physiol.65.092101.142131

Keshavan, 2009, Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a 1H spectroscopy study, Schizophr Res, 115, 88, 10.1016/j.schres.2009.08.012

Tibbo, 2004, 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia, Am J Psychiatry, 161, 1116, 10.1176/appi.ajp.161.6.1116

Yoo, 2009, Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus, Schizophr Res, 111, 86, 10.1016/j.schres.2009.03.036

Stone, 2009, Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume, Biol Psychiatry, 66, 533, 10.1016/j.biopsych.2009.05.006

Bartha, 1997, Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy, Arch Gen Psychiatry, 54, 959, 10.1001/archpsyc.1997.01830220085012

Bartha, 1999, A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients, Biol Psychiatry, 45, 1403, 10.1016/S0006-3223(99)00007-4

Bustillo, 2010, 1H-MRS at 4 Tesla in minimally treated early schizophrenia, Mol Psychiatry, 15, 629, 10.1038/mp.2009.121

Galinska, 2009, Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia, Med Sci Monit, 15, CR82

Ohrmann, 2005, Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study, Schizophr Res, 73, 153, 10.1016/j.schres.2004.08.021

Ohrmann, 2007, Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study, J Psychiatr Res, 41, 625, 10.1016/j.jpsychires.2006.07.002

Stanley, 1996, An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients, Schizophr Bull, 22, 597, 10.1093/schbul/22.4.597

Théberge, 2002, Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers, Am J Psychiatry, 159, 1944, 10.1176/appi.ajp.159.11.1944

Théberge, 2007, Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia, Br J Psychiatry, 191, 325, 10.1192/bjp.bp.106.033670

Wood, 2008, A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis, Schizophr Res, 102, 163, 10.1016/j.schres.2008.03.012

Olbrich, 2008, Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study, World J Biol Psychiatry, 9, 59, 10.1080/15622970701227811

Bustillo, 2011, Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla, Biol Psychiatry, 69, 19, 10.1016/j.biopsych.2010.08.024

Chang, 2007, Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction, Biol Psychiatry, 62, 1396, 10.1016/j.biopsych.2007.05.025

Choe, 1994, 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia, Acad Radiol, 1, 211, 10.1016/S1076-6332(05)80716-0

Lutkenhoff, 2010, Proton MRS in twin pairs discordant for schizophrenia, Mol Psychiatry, 15, 308, 10.1038/mp.2008.87

Öngür, 2008, Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania, Biol Psychiatry, 64, 718, 10.1016/j.biopsych.2008.05.014

Tayoshi, 2009, Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS), Schizophr Res, 108, 69, 10.1016/j.schres.2008.11.014

Tebartz van Elst, 2005, Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study, Biol Psychiatry, 58, 724, 10.1016/j.biopsych.2005.04.041

Théberge, 2003, Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS, Am J Psychiatry, 160, 2231, 10.1176/appi.ajp.160.12.2231

Rüsch, 2008, Neurochemical and structural correlates of executive dysfunction in schizophrenia, Schizophr Res, 99, 155, 10.1016/j.schres.2007.05.024

Shirayama, 2010, Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study, Neuroimage, 49, 2783, 10.1016/j.neuroimage.2009.10.031

Wood, 2007, Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3áT, Schizophr Res, 94, 328, 10.1016/j.schres.2007.05.008

Reid, Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia, Biol Psychiatry

Rowland, White matter alterations in deficit schizophrenia, Neuropsychopharmacology

Lipsey, 2001, The way in which intervention studies have “personality” and why it is important to meta-analysis, Eval Health Prof, 24, 236

Cohen, 1988, Statistical Power Analysis for the Behavioral Sciences

Hedges, 1985, Statistical Methods for Meta-Analysis

Comprehensive Meta-analysis, A Computer Program for Research Synthesis [Computer Program].

DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7:177

Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557

Huedo-Medina, 2006, Assessing heterogeneity in meta-analysis: q statistic or I2 index?, Psychol Methods, 11, 193, 10.1037/1082-989X.11.2.193

Olson, 2003, Relaxation effects in spectroscopic studies of schizophrenia, Psychiatric Neuroimaging, 79

McLoughlin, 2009, Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy, J Proteome Res, 8, 1943, 10.1021/pr800892u

Tkac, 2001, In vivo 1H NMR spectroscopy of the human brain at 7T, Magn Reson Med, 46, 451, 10.1002/mrm.1213

Steen, 2005, Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis, Neuropsychopharmacology, 30, 1949, 10.1038/sj.npp.1300850

Gaisler-Salomon, 2009, Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia, Neuropsychopharmacology, 34, 2305, 10.1038/npp.2009.58

Bak, 2006, The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer, J Neurochem, 98, 641, 10.1111/j.1471-4159.2006.03913.x

Iltis, Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized 1H MRS study, NMR Biomed

Rowland, 2005, Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study, Am J Psychiatry, 162, 394, 10.1176/appi.ajp.162.2.394

Mohn, 1999, Mice with reduced NMDA receptor expression display behaviors related to schizophrenia, Cell, 98, 427, 10.1016/S0092-8674(00)81972-8

Duncan, 2004, Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function, Behav Brain Res, 153, 507, 10.1016/j.bbr.2004.01.008

Tsien, 1996, The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory, Cell, 87, 1327, 10.1016/S0092-8674(00)81827-9

Nakazawa, 2003, Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one-time experience, Neuron, 38, 305, 10.1016/S0896-6273(03)00165-X

Niewoehner, 2007, Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus, Eu J Neurosci, 25, 837, 10.1111/j.1460-9568.2007.05312.x

Cheli, 2006, Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning, J Neurochem, 97, 68, 10.1111/j.1471-4159.2005.03592.x

Inada, 2003, Antisense hippocampal knockdown of NMDA-NR1 by HVJ-liposome vector induces deficit of prepulse inhibition but not of spatial memory, Neurosci Res, 45, 473, 10.1016/S0168-0102(03)00012-9

Inta, 2010, Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review, Neurosci Biobehav Rev, 34, 285, 10.1016/j.neubiorev.2009.07.010

Bannerman, 2008, NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory, J Neurosci, 28, 3623, 10.1523/JNEUROSCI.3639-07.2008

Sakimura, 1995, Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor [epsi]1 subunit, Nature, 373, 151, 10.1038/373151a0

Brigman, 2008, Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit, Learn Mem, 15, 50, 10.1101/lm.777308

Boyce-Rustay, 2006, Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice, Neuropsychopharmacology, 31, 2405, 10.1038/sj.npp.1301039

Spooren, 2004, Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition, Psychopharmacology, 175, 99, 10.1007/s00213-004-1785-y

von Engelhardt, 2008, Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks, Neuron, 60, 846, 10.1016/j.neuron.2008.09.039

Lisman, 2008, Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia, Trends Neurosci, 31, 234, 10.1016/j.tins.2008.02.005

Lewis, 2006, Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations, Arch Neurol, 63, 1372, 10.1001/archneur.63.10.1372

Fuchs, 2007, Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior, Neuron, 53, 591, 10.1016/j.neuron.2007.01.031

Gray, 2009, Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation, Int J Neuropsychopharmacol, 12, 45, 10.1017/S1461145708009085

Cartmell, 2000, Regulation of neurotransmitter release by metabotropic glutamate receptors, J Neurochem, 75, 889, 10.1046/j.1471-4159.2000.0750889.x

Patil, 2007, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial, Nat Med, 13, 1102, 10.1038/nm1632

Fell, 2008, Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039), J Pharmacol Exp Ther, 326, 209, 10.1124/jpet.108.136861

Szumlinski, 2005, Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia, Genes Brain Behav, 4, 273, 10.1111/j.1601-183X.2005.00120.x

Miyakawa, 2003, Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia, Proc Natl Acad Sci USA, 100, 8987, 10.1073/pnas.1432926100

Oni-Orisan, 2008, Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia, Biol Psychiatry, 63, 766, 10.1016/j.biopsych.2007.10.020

Smith, Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia, Neuroreport

Uezato, 2009, Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia, Bipolar Disord, 11, 711, 10.1111/j.1399-5618.2009.00752.x

Bauer, 2010, Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia, Schizophr Res, 117, 92, 10.1016/j.schres.2009.07.025

Jensen, 2002, Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla, Br J Psychiatry, 180, 39, 10.1192/bjp.180.1.39

Jensen, 2004, Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla, Br J Psychiatry, 184, 409, 10.1192/bjp.184.5.409

Miller, Longitudinal 4.0 Tesla 31P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia, Psychiat Res Neuroim